On Friday, Neurogene Inc (NASDAQ: NGNE) opened higher 30.21% from the last session, before settling in for the closing price of $15.59. Price fluctuations for NGNE have ranged from $12.49 to $74.49 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -20.00% annually for the last half of the decade. Company’s average yearly earnings per share was noted -245.34% at the time writing. With a float of $11.56 million, this company’s outstanding shares have now reached $12.82 million.
In an organization with 91 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -1896.11%, operating margin of -10552.11%, and the pretax margin is -7689.95%.
Neurogene Inc (NGNE) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Neurogene Inc is 22.21%, while institutional ownership is 83.62%.
Neurogene Inc (NGNE) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -245.34% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 25.10% during the next five years compared to -16.09% drop over the previous five years of trading.
Neurogene Inc (NASDAQ: NGNE) Trading Performance Indicators
Check out the current performance indicators for Neurogene Inc (NGNE). In the past quarter, the stock posted a quick ratio of 9.09. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 422.21.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.49, a number that is poised to hit -1.13 in the next quarter and is forecasted to reach -4.22 in one year’s time.
Technical Analysis of Neurogene Inc (NGNE)
Let’s dig in a bit further. During the last 5-days, its volume was 1.1 million. That was better than the volume of 0.16 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 6.26%. Additionally, its Average True Range was 6.39.
During the past 100 days, Neurogene Inc’s (NGNE) raw stochastic average was set at 9.76%, which indicates a significant increase from 9.76% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 344.76% in the past 14 days, which was higher than the 162.60% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $44.97, while its 200-day Moving Average is $38.77. However, in the short run, Neurogene Inc’s stock first resistance to watch stands at $22.33. Second resistance stands at $24.35. The third major resistance level sits at $27.78. If the price goes on to break the first support level at $16.88, it is likely to go to the next support level at $13.45. The third support level lies at $11.43 if the price breaches the second support level.
Neurogene Inc (NASDAQ: NGNE) Key Stats
There are currently 14,855K shares outstanding in the company with a market cap of 392.65 million. Presently, the company’s annual sales total 0 K according to its annual income of -36,320 K. Last quarter, the company’s sales amounted to 930 K and its income totaled -18,490 K.
